A new nanoparticle developed by OHSU researchers that makes cancer treatment safer and more effective. Michael Henderson, B.A., says the research “lays the foundation for a new kind of nanoparticle-based therapy that could improve how we approach hard-to-treat tumors.”

A groundbreaking advancement in cancer treatment has emerged from researchers at Oregon Health & Science University (OHSU), where a novel nanoparticle technology is poised to revolutionize the way high-intensity focused ultrasound (HIFU) is used against solid tumors.

A new nanoparticle developed by OHSU researchers that makes cancer treatment safer and more effective. Michael Henderson, B.A., says the research “lays the foundation for a new kind of nanoparticle-based therapy that could improve how we approach hard-to-treat tumors.”

In a BridgeBio Pharma, Inc., news release distributed by Globe Newswire about an early intervention for an inherited cardiovascular condition called transthyretin amyloid disease, Ahmad Masri, M.D., says, “I am hopeful that we can fill the significant gap in care for asymptomatic carriers of a genetic variant by providing potential preventative intervention early with resulting greater clinical benefit than addressing the disease at a later stage.”

The Columbian reports on a science career fair for high school students in Brush Prairie. Angela Wynia, P.A.-C., says the most challenging part of her career is keeping up with data and working with people: “People are wild cards. I can give two treatments to two different people, and they could react completely differently.” Story picked up by outlets across the Northwest.

Claudia Aime, D.N.P., RN, is celebrated among the top 50 women leaders of Oregon for 2025: Women We Admire.

Joel Nigg, Ph.D., is among leading experts interviewed by Gizmodo about the steadily rising prevalence of diagnoses for attention deficit hyperactivity disorder and variability of diagnosis from place to place nationwide.

In a Fierce Healthcare story about new free training offered by Epic to more efficiently handle electronic health records, Anne Petroski, M.S.N., RN, says, “I thought the class really filled a void in nurse training and will help health care organizations with strategies to improve training efficiency, which is especially valuable in today’s challenging budget constraints.”

Clinical Pain Advisor quotes Jennifer Mensik-Kennedy, Ph.D., RN, regarding a White House budget proposal eliminating the National Institute of Nursing Research in the Department of Health & Human Services: “[N]urses are concerned about the ability of a restructured HHS, without the NINR, to pursue nurse-specific approaches that answer the challenges and demanding needs of our health care system and the patients we serve.”

Five years ago, working in Portland, Dr. Vinay Prasad was throwing stones from the side of the road. Now he is behind the wheel — heading a pivotal science program for the Trump administration. Prasad, a former Oregon Health & Science University assistant professor, has been a vocal critic of the medical establishment as well as public health officials’ response to the COVID-19 pandemic. On Tuesday, he was named director of the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. That means he oversees the agency’s vaccines division.